6C8C

Chimeric Pol kappa RIR Rev1 C-terminal domain in complex with JHRE06


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.5 Å
  • R-Value Free: 0.191 
  • R-Value Work: 0.164 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.

Wojtaszek, J.L.Chatterjee, N.Najeeb, J.Ramos, A.Lee, M.Bian, K.Xue, J.Y.Fenton, B.A.Park, H.Li, D.Hemann, M.T.Hong, J.Walker, G.C.Zhou, P.

(2019) Cell 178: 152

  • DOI: 10.1016/j.cell.2019.05.028
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Intrinsic and acquired drug resistance and induction of secondary malignancies limit successful chemotherapy. Because mutagenic translesion synthesis (TLS) contributes to chemoresistance as well as treatment-induced mutations, targeting TLS is an att ...

    Intrinsic and acquired drug resistance and induction of secondary malignancies limit successful chemotherapy. Because mutagenic translesion synthesis (TLS) contributes to chemoresistance as well as treatment-induced mutations, targeting TLS is an attractive avenue for improving chemotherapeutics. However, development of small molecules with high specificity and in vivo efficacy for mutagenic TLS has been challenging. Here, we report the discovery of a small-molecule inhibitor, JH-RE-06, that disrupts mutagenic TLS by preventing recruitment of mutagenic POL ζ. Remarkably, JH-RE-06 targets a nearly featureless surface of REV1 that interacts with the REV7 subunit of POL ζ. Binding of JH-RE-06 induces REV1 dimerization, which blocks the REV1-REV7 interaction and POL ζ recruitment. JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice, establishing a framework for developing TLS inhibitors as a novel class of chemotherapy adjuvants.


    Organizational Affiliation

    The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA.,Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Biochemistry, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: peizhou@biochem.duke.edu.,The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: hemann@mit.edu.,Department of Chemistry, Duke University, Durham, NC 27708, USA.,Department of Chemistry, Duke University, Durham, NC 27708, USA; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: jiyong.hong@duke.edu.,Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: gwalker@mit.edu.,Trinity College of Arts & Sciences, Duke University, Durham, NC 27708, USA.,Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Chimeric protein of the Pol Kappa RIR helix and the Rev1 C-terminal domain
A, B
119Mus musculusMutation(s): 0 
Gene Names: Rev1 (Rev1l), Polk (Dinb1)
EC: 2.7.7.- 2.7.7.7
Find proteins for Q920Q2 (Mus musculus)
Go to UniProtKB:  Q920Q2
Find proteins for Q9QUG2 (Mus musculus)
Go to UniProtKB:  Q9QUG2
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
EQ7
Query on EQ7

Download SDF File 
Download CCD File 
B
8-chloro-2-[(2,4-dichlorophenyl)amino]-3-(3-methylbutanoyl)-5-nitroquinolin-4(1H)-one
C20 H16 Cl3 N3 O4
LRTXIQCBQIKIOH-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.5 Å
  • R-Value Free: 0.191 
  • R-Value Work: 0.164 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 48.550α = 90.00
b = 51.020β = 90.00
c = 98.920γ = 90.00
Software Package:
Software NamePurpose
XSCALEdata scaling
PHASERphasing
PHENIXrefinement
XDSdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data

  • Deposited Date: 2018-01-24 
  • Released Date: 2019-06-12 
  • Deposition Author(s): Najeeb, J., Zhou, P.

Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesCA191448

Revision History 

  • Version 1.0: 2019-06-12
    Type: Initial release
  • Version 1.1: 2019-06-26
    Type: Data collection, Database references
  • Version 1.2: 2019-07-10
    Type: Data collection, Database references
  • Version 1.3: 2019-12-04
    Type: Author supporting evidence